New Biotechnology Company: Immunovo BV

Immunovo BV secures seed funding from Dutch venture capital firms

29-Apr-2010 - Netherlands

Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and LUPUS Ventures BV. Immunovo combines features of synthetic immunogen development with the recent insights into mechanisms driving tumor growth and metastasis to create highly specific and powerful in vivo therapeutic immune responses.

The technology involves the application of novel and proprietary techniques in synthetic immunogen development. Immunovo is a spin-out from Pepscan Therapeutics in Lelystad. Its technology platform is based on the work of Pepscan’s founding scientist Professor Rob Meloen. The new company is managed by Dr. Joost van Bree (Chief Executive Officer) and Dr. Evert Jan Schenkelaars (Chief Medical Officer) and is based in ‘s-Hertogenbosch.

“We are truly excited to have created this exciting new company based upon such an innovative technology. Immunovo aims to develop its proprietary technology to create a pipeline of immunotherapeutic drugs which have the potential to be truly potent and effective medicines’’ said Joost van Bree.

As part of the seed funding, founding investors Jan van der Hoeven, Biox Biosciences and Cees de Wolff, Lupus Ventures, will join the Board of Directors.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance